pages:
-
A Phase 2 Randomized, Double Blind, Placebo-Controlled, Multiple Ascending dose study to evaluate Safety,Efficacy, and Pharmacokinetics and Pharmacodynamics of PF 06252616 in Ambulatory boys with Duchenne Muscular Dystrophy.
-
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Etrasimod in Adult Subjects with Eosinophilic Esophagitis
-
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of NP001 in Subjects with Amyotrophic Lateral Sclerosis (ALS) and Evidence of Elevated Systemic Inflammation
-
A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PROOF OF CONCEPT STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VIB4920 IN SUBJECTS WITH SJOGREN'S SYNDROME (SS)
-
A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients with Mild to Moderate Pneumonia due to COVID-19
-
A phase 2 randomized, open-label, parallel group study to assess the immunogenicity, safety, and tolerability of Moderna mRNA-1273 vaccine administered with casirivimab+imdevimab in healthy adult volunteers
Research Grant
-
A Phase 2 Study for the Evaluation of Safety and Efficacy of Humacyte¿s Human Acellular Vessel for Use as a Vascular Prosthesis for Femoro-Popliteal Bypass in Patients with Peripheral Arterial Disease
-
A Phase 2 study of ADXS11-001 i subjects with persistent/recurrent loco-regional or metastatic squamous cell carcinoma of the anorectal canal.
-
A Phase 2 Study of Nivolumab in combination with either Rucaparib, docetaxel, or enzalutamide in men with Castration-resistant metastaic prostate cancer (CheckMate 9KD: CHECKpoint pathway and nivoluMA
-
A Phase 2 Study of osimertinib in combination with selumetinib in EGFR inhibitor naive advanced EGFR mutant lung cancer
-
A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
-
A Phase 2 Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line Treatment of Patients with Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
-
A Phase 2 Study of Sitravatinib in Combination with Nivolumab in Patients with Advanced or Metastatic Urothelial Carcinoma (Mirati 516-003)
-
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy
-
A Phase 2 Study to Assess the Safety, Tolerability, Exploratory Efficacy, and Pharmacokinetics of Orally Administered JBPOS0101 for Refractory Infantile Spasms Patients
-
A PHASE 2 STUDY TO ASSESS THE VIROLOGIC EFFICACY OF
REGN10933+REGN10987 ACROSS DIFFERENT DOSE REGIMENS IN
OUTPATIENTS WITH SARS-CoV-2 INFECTION
-
A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer
-
A Phase 2 Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients with Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer
-
A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (ADHERE)
-
A Phase 2, Double-Blind, Double-Dummy, Placebo-Controlled, Multicenter Study of the Efficacy, Safety, and Tolerability of NM-002 in Adult Patients with Short Bowel Syndrome
-
A Phase 2, Double-blind, Randomized, Placebo-controlled Milticenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
-
A Phase 2, Double-blind, Randomized, Placebo-controlled Milticenter Study to Evaluate Efficacy, Safety, and Tolerability of JBT-101 in Systemic Lupus Erythematosus
Research Grant
-
A Phase 2, multi-center, randomized, double blind, placebo controlled study in subjects with late prodromal and early manifest Huntington Disease )HD) to assess the safety, tolerability, pharmacokinetics, and efficacy of VX15/2503
-
A PHASE 2, MULTICENTER, MULTI-COHORT, OPEN-LABEL STUDY OF POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE OR POMALIDOMIDE IN COMBINATION WITH LOW-DOSE DEXAMETHASONE AND DARATUMUMAB IN SUBJECTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA
-
A Phase 2, Multicenter, Open Label Study To Measure Safety Donor Lungs (EVLP)
-
A Phase 2, Multicenter, Open-Label Study to Assess Appropriate Dosing and to Evaluate Safety of Crizanlizumab, with or without Hydroxyurea/Hydroxycarbamide, in Sequential, Descending Age Groups of Pediatric Sickle Cell Disease Patients with Vaso-Occl
-
A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination and Ribavirin for 12 Weeks in Subjects with Chronic HCV Infection and Child-Pugh-Turcotte Class Cirrhosis
-
A Phase 2, Multicenter, Open-Label Study to Investigate the Safety and Efficacy of Sofosbuvir/Ledipasvir
-
A Phase 2, Multicenter, Open-Label, Randomized Study Comparing INCB-50465, a PI3K8 Inhibitor, to Idelalisib in Relapsed or Refractory Follicular Lymphoma (CITADEL-203)
-
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to AMD
Research Grant
pages: